A pharmaceutical composition for preventing or treating chemotherapy-induced cystitis

A composition and technology for cystitis, applied in the field of pharmaceutical compositions for cystitis, can solve the problems of no better preventive drugs for cystitis, limit the dosage and long-term administration of chemotherapy drugs, lack of broad-spectrum preventive drugs, etc., and achieve prevention effect, wide range of therapeutic effects

Inactive Publication Date: 2011-11-30
济南环肽医药科技有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no good preventive drug for cystitis caused by mitomycin, cantharidin, camptothecin, etc.
For cystitis caused by chemotherapy drugs, except for a few narrow-spectrum preve

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition for preventing or treating chemotherapy-induced cystitis
  • A pharmaceutical composition for preventing or treating chemotherapy-induced cystitis
  • A pharmaceutical composition for preventing or treating chemotherapy-induced cystitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Preparation of 1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid and mesna composition tablet

[0022] The recipe is as follows:

[0023]

[0024] Pass the prescribed 1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid and mesna through a 150μm sieve, and pass the auxiliary materials through a 180μm sieve for use; now use 1,4,5,6-tetrahydro- 2-Methyl-4-pyrimidine carboxylic acid is mixed with microcrystalline cellulose, and then mixed with lactose, sodium carboxymethyl starch, polyvinylpyrrolidone and magnesium stearate successively, and the mixture is uniform and then pressed into tablets.

Embodiment 2

[0025] Example 2 Preparation of 1,4,5,6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid and mesna composition tablet

[0026]

[0027] Pass the prescribed 1,4,5,6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid and mesna through a 180 μm sieve for use; pass the sieved 1,4,5,6-tetrahydro -2-Methyl-5-hydroxy-4-pyrimidine carboxylic acid is mixed with microcrystalline cellulose, sodium carboxymethyl starch and polyvinylpyrrolidone and pressed into large tablets. Sodium dialkyl sulfate and micropowder silica gel can be mixed and pressed into tablets.

Embodiment 3

[0028] Example 3 Preparation of 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carboxylic acid and mesna composition injection

[0029]

[0030]

[0031] Mix the 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carboxylic acid, mesna and polyvinylpyrrolidone of the prescription amount, add 800ml of water for injection, then add activated carbon, filter to remove the carbon, then Add water for injection to 1000ml, fine filtration, potting, and sterilize at 115°C for 30 minutes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition for preventing or treating cystitis caused by chemotherapy. The medicinal composition consists of mesna, 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid or a 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid derivative and a pharmaceutically acceptable medicinal carrier. The combined medication of the 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid as well as the derivative thereof and the mesna has an unexpected therapeutic effect on preventing or treating the cystitis caused by a chemotherapeutic medicament. The medicinal composition contributes to relieving the pain of a chemotherapy patient; and the tolerance dose of the patient to the chemotherapeutic medicament is improved. Compared with the conventional medicamentssuch as the mesna and the like, the medicinal composition has the advantages that: the composition of the 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid as well as the derivative thereof and the mesna has a wide therapeutic effect on the cystitis caused by the chemotherapeutic medicament and has a limited prevention effect.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating induced cystitis. Background technique [0002] Tumor is one of the common diseases that threaten human health. The research on tumors has made great progress, and a variety of radiotherapy, chemotherapy and other methods have been developed for the treatment of tumors. However, various drugs and therapies have limitations, it is difficult to achieve ideal results, and drug resistance is prone to occur. and side effects. Cancer mortality still ranks first among all diseases. [0003] Statistics show that 3 million people died of cancer in my country in 2006, and the incidence of cancer is still on the rise. According to statistics, in less than 20 years, the incidence of cancer in my country has increased by 69%, and the mortality rate has increased by 29.4%. Therefore, researching new and effective tumor therapeutic drugs is still the main direction of current...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/505A61K31/185A61P13/10
Inventor 厉凌子厉保秋
Owner 济南环肽医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products